← Leaderboards
William Charles Spanos
Sanford Research/Usd
$4,935,118
Attributed
$7,661,684
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–24$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,661,684 · 4
By mechanism
R01$5,453,132 · 2
P20$1,436,752 · 1
K08$771,800 · 1
Top collaborators
- Dohun Pyeon9 shared
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusTumorHead And Neck CancerCellsMediatingMouse ModelMalignant NeoplasmsImmuneNeoplastic CellHead And Neck Squamous Cell CarcinomaCell SurfaceImmunotherapyT-LymphocyteImmune ResponseCancer EtiologyCancer CellRadiationT Cell ResponseIn VivoCd8-Positive T-LymphocytesAntibodiesCessation Of LifeAdenovirusesImmunity
Grant awards (19)
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$643,133
R01 · FY2024 · DE
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$656,258
R01 · FY2023 · DE
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$641,281
R01 · FY2022 · DE
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$657,132
R01 · FY2021 · DE
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$626,815
R01 · FY2020 · DE
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$510,770
R01 · FY2020 · DE
Cisplatin Mediated Immune Modulation of HPV Positive Head and Neck Cancer$283,507
P20 · FY2020 · GM · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$524,441
R01 · FY2019 · DE
Cisplatin Mediated Immune Modulation of HPV Positive Head and Neck Cancer$284,153
P20 · FY2019 · GM · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$668,326
R01 · FY2018 · DE
Cisplatin Mediated Immune Modulation of HPV Positive Head and Neck Cancer$284,314
P20 · FY2018 · GM · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$524,976
R01 · FY2017 · DE
Cisplatin Mediated Immune Modulation of HPV Positive Head and Neck Cancer$292,389
P20 · FY2017 · GM · contact PI
Cisplatin Mediated Immune Modulation of HPV Positive Head and Neck Cancer$292,389
P20 · FY2016 · GM · contact PI
Mechanism of Radiation Mediated Clearance of HPV Positive Head and Neck Cancer$154,360
K08 · FY2015 · CA · contact PI
Mechanism of Radiation Mediated Clearance of HPV Positive Head and Neck Cancer$154,360
K08 · FY2014 · CA · contact PI
Mechanism of Radiation Mediated Clearance of HPV Positive Head and Neck Cancer$154,360
K08 · FY2013 · CA · contact PI
Mechanism of Radiation Mediated Clearance of HPV Positive Head and Neck Cancer$154,360
K08 · FY2012 · CA · contact PI
Mechanism of Radiation Mediated Clearance of HPV Positive Head and Neck Cancer$154,360
K08 · FY2011 · CA · contact PI